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Abstract 
LATS1 tumor suppressor is a serine/threonine kinase 
of the AGC kinase family and a core component of 
the Hippo pathway in mammals.  LATS1 regulates 
various biological processes such as cell cycle 
progression, genetic stability, cell motility and 
adhesion, apoptosis, stem cell renewal and 
differentiation (Visser and Yang, 2010; Mo et al., 
2014).  
LATS1 performs these functions by phosphorylating 
various substrates such as transcriptional co-
activators YAP and TAZ (Zhao et al., 2007; Hao et 
al., 2008).   
LATS1 is also required for tissue homeostasis in 
both flies and mice (Visser et al., 2010).  
In addition to its roles in a broad spectrum of normal 
biological processes, loss of LATS1 has been shown 
to be important for the development of cancer and 
resistance to chemotherapeutic drugs (Visser et al., 
2010). 
Therefore, understanding the molecular mechanisms 
underlying loss-of-LATS1-induced tumorigenesis 
and drug resistance will shed light on the design of 
new cancer treatment strategies in the future. 
Identity 
Other names: Warts 
HGNC (Hugo): LATS1 
Location: LATS1 is localized to chromosome 6q24-
25.1 
Local order: KATNA1. . LATS1. . LOC645967. . 
NUP43 
DNA/RNA 
Description 
The LATS1 gene contains 8 exons, ranging in size 
from 106 bp to 1513 bp.  The mRNA transcript spans 
4756 bp (NM_004690). 
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Protein 
Transcription 
An alternatively spiced variant was identified in 
vertebrate retina and testis.  This smaller variant has 
deletions of exon 6, 7, and 8 (NM_001270519). 
Furthermore, a non-coding third transcript variant 
that is comprised of alternate 5' and internal exons 
has recently been proposed to exist (NR_073033). In 
this transcript, an upstream open reading frame 
(ORF) is predicted to interfere with translation of the 
longer ORF. The functional significance of these 
splice variants remains unclear. 
Description 
LATS1 is a highly conserved Ser/Thr kinase that 
belongs to the AGC (Protein kinase A/G/C) family 
of protein kinases.  
Within the C-terminal kinase domain lie two 
conserved residues, Ser909 and Thr1079, which are 
phosphorylated upon activation.  
The N-terminus of LATS1 contains two PPxY 
motifs, which bind to WW-domain transcriptional 
co-activators TAZ and YAP or E3 ubiquitin ligases 
ITCH, WWP1, and NEDD4 as well as a protein 
binding domain (PBD) that has been shown to bind 
to MOB1 and cytoskeletal proteins LIMK1 and 
Zyxin.  
In addition, an ubiquitin binding domain (UBA) and 
a proline-rich region (P-stretch) have been identified 
in the N-terminal region of LATS1, although the 
functional significance of these domains has not yet 
been determined. 
Expression 
LATS1 is ubiquitously expressed. 
Localisation 
LATS1 is primarily localized within the cytoplasm, 
however, LATS1 possesses functions that require its 
translocation to the nucleus. The mechanism of 
translocation is not yet understood. 
Function 
As a tumor suppressor, LATS1 functions as a key 
regulator of cell cycle progression, apoptosis, and 
cell migration. As cell cycle regulator, LATS1 is 
able to modulate multiple aspects of the cell cycle, 
including G2/M arrest, mitotic exit, activation of the 
G1 tetraploidy checkpoint, and regulation of 
cytokinesis. LATS1 also promotes apoptosis by 
inducing expression of pro-apoptotic proteins BAX, 
caspase 3 and tumor suppressor p53. Finally, loss of 
LATS1 has been shown to enhance the rate of cell 
migration. 
HIPPO Signaling Pathway LATS1 is a key player 
in the conserved Hippo signaling pathway. Core 
components of this pathway include the adaptor 
proteins Sav1 and MOB1, which aid in bringing 
LATS in contact with the kinase MST1/2. MST1/2 
can then phosphorylate and activate LATS1. 
Upstream core components of the Hippo pathway 
lay FERM domain proteins Willin/FRMD6 and 
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Merlin/NF2, as well as a protocadherin FAT4 and G-
protein-coupled receptor (GPCR) and many other 
regulators (see Figure). Downstream of LATS1 lay 
two transcriptional co-activators, YAP and TAZ, 
which are phosphorylated and inhibited by LATS1, 
thereby sequestering them in the cytoplasm. Finally, 
YAP and TAZ have been shown to act through the 
TEAD/TEF family of transcription factors to 
modulate the expression of a variety of genes (See 
Figure). Functionally, the Hippo pathway has been 
implicated in cell proliferation, apoptosis, the 
epithelial mesenchymal transition, cell migration, 
and stem cell differentiation and renewal. 
Homology 
The LATS1 kinase domain is conserved across 
species. Human homologs include LATS2 and the 
nuclear Dbf2-related kinases, NDR1 and NDR2. 
Mutations 
The Catalogue of Somatic Mutations in Cancer 
(COSMIC), lists 491 unique mutations in the LATS1 
gene. In the COSMIC Cell Lines Project, there are 
135 unique mutations in the LATS1 gene listed. 
Implicated in 
Breast cancer 
In breast cancers, loss of heterozygosity is often 
observed on chromosome 6q suggesting a role for 
LATS1 in breast cancer carcinogenesis (Morinaga et 
al., 2000).  In a study of breast cancer patients, low 
LATS1 expression has been associated with a 
biologically aggressive phenotype (Takahashi et al., 
2005). In a study of breast cancer tissues, the LATS1 
promoter was found to be hypermethylated in 56.7% 
(17/30) of tumors causing a significant decrease in 
LATS1 mRNA expression. In breast cancer patients, 
decreased LATS1 mRNA expression was associated 
with large tumor size, lymph node metastasis, and 
estrogen and progesterone negativity.  Thus, loss of 
LATS1 is associated with poor prognosis in breast 
cancer. 
Cervical cancer 
In clinical samples of normal and neoplastic cervix, 
increased expression of upstream regulator ITCH 
and decreased expression of LATS1 was associated 
with transformation of cervical epithelial cells and 
progression of cervical squamous cell carcinoma 
(Zhou et al., 2014). In cervical cancer patients high 
ITCH or low LATS1 expression was associated with 
increased clinical stage and tumor size. Recently, 
miRNA-21 (miR-21) was found to regulate LATS1 
to promote radioresistance in HR-HPV positive 
cervical cancer implicating LATS1 in cervical 
cancer sensitivity to treatment (Liu et al., 2015). 
Ovarian cancer 
Lats1 deficient mice develop soft-tissue sarcomas as 
well as ovarian stromal cell tumours (St John et al., 
1999). In human ovarian cancer, reduced LATS1 
expression has been observed in ovarian serous 
borderline cystadenomas and ovarian serous 
carcinoma while the opposite pattern is found in 
ovarian mucinous borderline cystadenomas and 
ovarian mucinous carcinoma (Xu et al., 2015). In 
clear cell carcinoma, LATS1 expression was 
decreased. In ovarian serous carcinoma (but not in 
mucinous or clear cell carcinomas), LATS1 
expression levels were correlated with disease 
recurrence, clinical stage and tumor grade. 
Renal cell carcinoma 
LATS1 mRNA expression is reduced in samples 
from renal cell carcinoma patients (Chen et al., 
2014). In these patients, LATS1 expression was 
associated with cancer pathological grade and 
clinical stage. The renal cancer cell line 786-O shows 
hypermethylation of the LATS1 promoter and 
pharmacological demethylation of the promoter in 
786-O reduced cell proliferation while increasing 
apoptosis and G1 arrest. 
Bladder cancer 
A recent study identified 29 total and 18 novel single 
nucleotide polymorphisms (SNPs) in the LATS1 
gene using tissues from urinary bladder or colon 
cancer patients (Saadeldin et al., 2015). 13 SNPs 
mapped to intronic and untranslated sequences while 
5 SNPs mapped to the coding sequences of LATS1 
with 4/5 of these novel SNPs representing missense 
mutations in the serine/threonine kinase catalytic 
domain of LATS1. The functional significance of 
these mutations remains unclear. 
Colon cancer 
In tissue from patients with colorectal cancer, the 
LATS1 gene was found to be hypermethylated in 
57% (25/44) of cases and this hypermethylation was 
associated with decreased LATS1 mRNA levels 
(Wierzbicki et al., 2013). 89.4% (127/142) of all 
colorectal cancer samples analyzed showed 
decreased LATS1 mRNA. Another study identified 
18 novel SNPs in the LATS1 gene using tissues from 
urinary bladder or colon cancer patients (Saadeldin 
et al., 2015). 13 SNPs mapped to intronic and 
untranslated sequences while 5 SNPs mapped to the 
coding sequences of LATS1 with 4/5 of these novel 
SNPs representing missense mutations in the 
serine/threonine kinase catalytic domain of LATS1. 
The functional significance of these SNPs remains 
poorly understood. 
Lung cancer 
In Japanese lung cancer patients, the LATS1 
promoter has been found to be hypermethylated in 
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79.8% (95/119) of tumors (Sasaki et al., 2010). In 
this study, the methylation status of the LATS1 
promoter was associated with squamous histology 
and smoking status but not patient survival. In a 
study of non-small cell lung cancer (NSCLC), 
LATS1 expression is higher in normal lung tissue 
than in samples from NSCLC tumors (Lin et al., 
2014). Low LATS1 expression in NSCLC patients 
was associated with higher p-TMN stage, increased 
lymph node metastasis and shorter overall survival. 
LATS1 overexpression in NSCLC cell lines reduces 
cell proliferation and invasion. 
Nervous system tumors 
LATS1 has been reported to be downregulated in 
human astrocytomas by promoter hypermethylation 
(Jiang et al., 2006). In tissues from astrocytomas, 
63.66% (56/88) showed hypermethylation of the 
LATS1 promoter while no methylation of the 
LATS1 promoter was found in 10 normal brain 
controls. The LATS1 mRNA level was significantly 
decreased in hypermethylated astrocytoma tissues 
compared to unmethylated controls. A similar study 
has shown that LATS1 is downregulated in gliomas 
(Ji et al., 2012). In gliomas, decreased LATS1 
expression was correlated with higher WHO grade, 
lower Karnofsky Performance Status and shorter 
overall survival. Therefore, LATS1 is an 
independent prognostic indicator for survival of 
glioma patients. In the glioma cell line U251, 
overexpression of LATS1 reduced cell proliferation, 
migration and invasion. Recently, a germline LATS1 
mutation (c.286C>T; p.R96W) was identified in a 
family with Li-Fraumeni syndrome (TP53 germline 
mutation), a MSH4 germline mutation and  multiple 
cases of nervous system tumours (Kim et al., 2014). 
Peripheral shwannomas were observed in family 
members lacking the TP53 mutation but who instead 
carried mutations in MSH4 and LATS1. To examine 
how LATS1 might drive sporadic nervous system 
tumorigenesis, the authors screened 81 sporadic 
nervous system patients for mutations in the LATS1 
gene but only identified one such case (a spinal 
schwannoma with c.2480delG; p.*R827Kfs*8). 
Head and neck squamous cell 
carcinoma (HNSCC) 
LATS1 is one of 15 tumor-related genes that 
frequently show promoter hypermethylation in 
HNSCC (Steinmann et al. 2009). Increased 
methylation of these tumor-related genes is 
associated with less cellular differentiation and 
higher tumor stage. 
Oral squamous cell carcinoma 
A pilot study in India examined the methylation 
status of the LATS1 gene in tumor samples from 13 
patients with oral squamous cell carcinoma (Reddy 
et al., 2015). 54% (7/13) of tumor samples showed 
hypermethylation of the LATS1 gene. 
Soft-tissue sarcoma 
Lats1 deficient mice develop soft-tissue sarcomas as 
well as ovarian stromal cell tumours (St John et al., 
1999).  
Further, in multiple subtypes of human soft tissue 
sarcoma (myxoid liposarcoma, leiomyosarcoma and 
malignant fibrous histiocytoma), a missense point 
mutation in LATS1 gene locus and reduced LATS1 
mRNA levels have been observed (Hisaoka et al., 
2002). This decreased expression was suggested to 
be the result of promoter hypermethylation. 
Nevoid basal cell carcinoma 
syndrome (NBCCS) 
A recent case report describes biallelic disruptions of 
the LATS1 gene in tissues from a patient with 
NBCCS (Tate et al., 2014). The authors compared 
superficial basal cell carcinoma (BCC) cells with 
more infiltrative BCCs by whole-exome sequencing. 
The infiltrative but not superficial BCCs showed 
mutations in the LATS1 gene. Specifically, 
infiltrative BCCs had one allele with the nonsense 
mutation c.943C>T (p.Q315X) as well as the loss of 
the other wild-type allele of LATS1. Loss of 
heterozygosity analysis showed a deletion in the 
distal region of chromosome 6q. 
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